Latest Period
Q1 2026
Security Snapshot
BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN) Institutional Ownership
CUSIP: 09061G101
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
553
Shares (Excl. Options)
183,626,619
Price
$56.49
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- BMRN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 183,626,619
- Total 13F value
- $10,366,939,900
- Portfolio coverage rank
- 0.01%
- Share change
- -5,939,410
- Value change
- -$369,857,341
- Number of holders
- 553
- Shares outstanding
- 192,632,743
- SEC-reported price per share
- $57.22
- Insider filing price
- $57.22
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock is tracked under CUSIP 09061G101.
- 553 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 553 to 7 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $10,366,939,900 to $1,128,847.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 553 institutions filings for Q1 2026.
Security key
09061G101
Latest holder period
Q1 2026
13F holders
553
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
BMRN full holder history
BIOMARIN PHARMACEUTICAL INC SEC filings
BIOMARIN PHARMACEUTICAL INC company facts
BIOMARIN PHARMACEUTICAL INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09061G101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
BMRN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 9.1% | -15% | $1,043,635,432 | -$181,821,806 | 17,560,751 | -15% | BlackRock, Inc. | 31 Dec 2025 |
| PRIMECAP MANAGEMENT CO/CA/ | 8.2% | $906,812,938 | 15,795,383 | PRIMECAP MANAGEMENT CO/CA/ | 30 Jun 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $571,295,741 | 10,113,219 | Vanguard Capital Management | 31 Mar 2026 | |||
| Capital Research Global Investors | 4.8% | -29% | $576,308,252 | -$241,913,549 | 9,150,655 | -30% | Capital Research Global Investors | 31 Mar 2025 |
| VIKING GLOBAL INVESTORS LP | 4.3% | -35% | $450,729,215 | -$214,821,957 | 8,322,179 | -32% | VIKING GLOBAL INVESTORS LP | 30 Sep 2025 |
As of 31 Mar 2026, 553 institutional investors reported holding 183,626,619 shares of BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN). This represents 95% of the company’s total 192,632,743 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
66%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10% | 19,818,301 | +3.6% | 0.02% | $1,119,535,796 |
| Dodge & Cox | 7.6% | 14,561,759 | -0.07% | 0.45% | $822,593,766 |
| PRIMECAP MANAGEMENT CO/CA/ | 7.4% | 14,194,005 | -2.4% | 0.63% | $801,819,344 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 8,643,164 | 0% | 0.01% | $488,252,334 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 8,298,475 | 0% | 0.02% | $468,780,853 |
| AQR CAPITAL MANAGEMENT LLC | 4% | 7,676,541 | +15% | 0.2% | $429,348,929 |
| STATE STREET CORP | 3.8% | 7,295,079 | -3% | 0.01% | $412,099,013 |
| VIKING GLOBAL INVESTORS LP | 3.7% | 7,062,077 | +17% | 1.1% | $398,936,730 |
| CITADEL ADVISORS LLC | 2.3% | 4,512,634 | +231% | 0.18% | $254,918,695 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 3,819,441 | +4% | 0.01% | $215,809,244 |
| DIMENSIONAL FUND ADVISORS LP | 2% | 3,802,930 | +14% | 0.04% | $214,803,851 |
| Vestal Point Capital, LP | 1.9% | 3,575,000 | +19% | 5.6% | $201,951,750 |
| FMR LLC | 1.9% | 3,567,031 | +94% | 0.01% | $201,501,556 |
| Capital Research Global Investors | 1.8% | 3,491,386 | +37% | 0.03% | $197,228,395 |
| MILLENNIUM MANAGEMENT LLC | 1.6% | 3,010,308 | -0.9% | 0.13% | $170,052,299 |
| Assenagon Asset Management S.A. | 1% | 1,920,658 | +35% | 0.17% | $108,497,970 |
| FIRST TRUST ADVISORS LP | 0.87% | 1,672,491 | +43% | 0.07% | $94,478,985 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.82% | 1,587,683 | +12% | 0.01% | $89,688,213 |
| NORTHERN TRUST CORP | 0.82% | 1,586,384 | +2.5% | 0.01% | $89,614,833 |
| UBS Group AG | 0.78% | 1,496,852 | -32% | 0.02% | $84,557,169 |
| Balyasny Asset Management L.P. | 0.71% | 1,362,752 | 0.15% | $76,981,860 | |
| MORGAN STANLEY | 0.69% | 1,321,665 | -43% | 0% | $74,660,928 |
| Jones Hill Capital LP | 0.66% | 1,268,390 | 0% | 15% | $71,651,351 |
| DNB Asset Management AS | 0.63% | 1,221,387 | -10% | 0.25% | $68,996,152 |
| Point72 Asset Management, L.P. | 0.62% | 1,199,206 | +173% | 0.12% | $67,743,147 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 19,735 | $1,128,847 | +$143,140 | $57.22 | 7 |
| 2026 Q1 | 183,626,619 | $10,366,939,900 | -$369,857,341 | $56.49 | 553 |
| 2025 Q4 | 187,901,687 | $11,155,225,667 | +$559,342,824 | $59.43 | 535 |
| 2025 Q3 | 179,472,067 | $9,720,162,187 | -$257,275,980 | $54.16 | 572 |
| 2025 Q2 | 184,517,274 | $10,145,314,583 | +$90,429,124 | $54.97 | 576 |
| 2025 Q1 | 181,117,177 | $12,795,609,480 | -$83,582,224 | $70.69 | 576 |
| 2024 Q4 | 183,186,403 | $12,041,547,200 | +$135,391,046 | $65.73 | 536 |
| 2024 Q3 | 180,328,429 | $12,672,555,041 | -$377,350,661 | $70.29 | 545 |
| 2024 Q2 | 184,765,128 | $15,210,183,330 | -$88,804,857 | $82.33 | 555 |
| 2024 Q1 | 186,676,383 | $16,305,278,098 | +$52,133,744 | $87.34 | 550 |
| 2023 Q4 | 185,955,477 | $17,930,401,770 | +$422,069,685 | $96.42 | 540 |
| 2023 Q3 | 181,505,269 | $16,056,450,996 | +$288,283,093 | $88.48 | 513 |
| 2023 Q2 | 178,653,463 | $15,494,286,845 | -$55,787,524 | $86.68 | 548 |
| 2023 Q1 | 179,051,547 | $17,400,388,762 | -$352,972,540 | $97.24 | 544 |
| 2022 Q4 | 182,911,512 | $18,940,963,403 | +$57,088,463 | $103.49 | 570 |
| 2022 Q3 | 182,236,184 | $15,455,338,348 | +$265,782,383 | $84.77 | 535 |
| 2022 Q2 | 179,167,298 | $14,847,543,178 | +$141,628,422 | $82.87 | 525 |
| 2022 Q1 | 177,887,694 | $13,719,376,304 | +$56,012,733 | $77.10 | 543 |
| 2021 Q4 | 177,134,050 | $15,645,638,303 | +$125,285,951 | $88.35 | 539 |
| 2021 Q3 | 175,999,345 | $13,600,848,412 | +$49,734,828 | $77.29 | 498 |
| 2021 Q2 | 176,035,547 | $14,685,174,801 | -$129,382,414 | $83.44 | 510 |
| 2021 Q1 | 177,743,163 | $13,419,458,431 | -$323,613,922 | $75.51 | 513 |
| 2020 Q4 | 182,409,125 | $15,984,411,685 | +$294,129,377 | $87.69 | 519 |
| 2020 Q3 | 179,647,602 | $13,663,308,058 | -$318,133,163 | $76.08 | 487 |
| 2020 Q2 | 180,885,676 | $22,304,634,235 | +$749,303,824 | $123.34 | 516 |